Characterization of a Neisseria gonorrhoeae Ciprofloxacin panel for an antimicrobial resistant Isolate Bank

Liu, Hsi; Tang, Kevin; Pham, Cau D.; Schmerer, Matthew; Kersh, Ellen N.; Raphael, Brian

doi:10.1371/journal.pone.0264149

Cited by 2 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2012, dual treatment with azithromycin and ceftriaxone was introduced. Yet, a significant increase in azithromycin resistance worldwide and the identification of a very highlevel resistance (> 512 μg/mL) has prompted the reversal of this recommendation [9][10][11] . At the end of 2020, ceftriaxone monotherapy was decided as the recommended therapy for noncomplicated gonorrhoea in the US 12 .…”

Section: Introductionmentioning

confidence: 99%

Rapid molecular phenotypic antimicrobial susceptibility test forNeisseria gonorrhoeaebased on propidium monoazide viability PCR

Tjandra

Ram-Mohan

Abe

et al. 2023

Preprint

View full text Add to dashboard Cite

Neisseria gonorrhoeae(NG) is an urgent threat to antimicrobial resistance (AMR) worldwide. NG has acquired rapid resistance to all previously recommended treatments leaving ceftriaxone monotherapy as the first and last line of therapy for uncomplicated NG. The ability to rapidly determine susceptibility, which is currently nonexistent for NG, has been proposed as a strategy to preserve ceftriaxone by using alternative treatments. Herein, we used a DNA-intercalating dye in combination with NG-specific primers/probes to generate qPCR cycle threshold (Ct) values at different concentrations of 2 NG-relevant antimicrobials. Our proof of concept dual-antimicrobial logistic regression model based on the differential Ct measurements achieved an AUC of 0.93 with a categorical agreement for susceptibility of 84.6%. When surveying the performance against each antimicrobial separately, the model predicted 90% and 75% susceptible and resistant strains respectively to ceftriaxone and 66.7% and 83.3% susceptible and resistant strains respectively to ciprofloxacin. We further validated the model against the individual replicates and determined the accuracy of the model in classifying susceptibility agnostic of the inoculum size. We demonstrated a novel PCR-based approach to determine phenotypic ciprofloxacin and ceftriaxone susceptibility information for NG with reasonable accuracy in under 30 min, a significant improvement compared to the conventional method which takes 3 days.Table of Content Graphic

show abstract

Section: Introductionmentioning

confidence: 99%

Rapid molecular phenotypic antimicrobial susceptibility test forNeisseria gonorrhoeaebased on propidium monoazide viability PCR

Tjandra

Ram-Mohan

Abe

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…In 2012, dual treatment with azithromycin and ceftriaxone was introduced. Yet, a significant increase in azithromycin resistance worldwide and the identification of a very high-level resistance (>512 μg/mL) have prompted the reversal of this recommendation. − At the end of 2020, ceftriaxone monotherapy was decided as the recommended therapy for noncomplicated gonorrhea in the US …”

mentioning

confidence: 99%

Rapid Molecular Phenotypic Antimicrobial Susceptibility Test for Neisseria gonorrhoeae Based on Propidium Monoazide Viability PCR

et al. 2023

View full text Add to dashboard Cite

Neisseria gonorrhoeae (NG) is an urgent threat to antimicrobial resistance (AMR) worldwide. NG has acquired rapid resistance to all previously recommended treatments, leaving ceftriaxone monotherapy as the first and last line of therapy for uncomplicated NG. The ability to rapidly determine susceptibility, which is currently nonexistent for NG, has been proposed as a strategy to preserve ceftriaxone by using alternative treatments. Herein, we used a DNA-intercalating dye in combination with NG-specific primers/probes to generate qPCR cycle threshold (Ct) values at different concentrations of 2 NG-relevant antimicrobials. Our proof-of-concept dual-antimicrobial logistic regression model based on the differential Ct measurements achieved an AUC of 0.93 with a categorical agreement for the susceptibility of 84.6%. When surveying the performance against each antimicrobial separately, the model predicted 90 and 75% susceptible and resistant strains, respectively, to ceftriaxone and 66.7 and 83.3% susceptible and resistant strains, respectively, to ciprofloxacin. We further validated the model against the individual replicates and determined the accuracy of the model in classifying susceptibility agnostic of the inoculum size. We demonstrated a novel PCR-based approach to determine phenotypic ciprofloxacin and ceftriaxone susceptibility information for NG with reasonable accuracy within 30 min, a significant improvement compared to the conventional method which could take multiple days.

show abstract

Characterization of a Neisseria gonorrhoeae Ciprofloxacin panel for an antimicrobial resistant Isolate Bank

Cited by 2 publications

References 21 publications

Rapid molecular phenotypic antimicrobial susceptibility test forNeisseria gonorrhoeaebased on propidium monoazide viability PCR

Rapid molecular phenotypic antimicrobial susceptibility test forNeisseria gonorrhoeaebased on propidium monoazide viability PCR

Rapid Molecular Phenotypic Antimicrobial Susceptibility Test for Neisseria gonorrhoeae Based on Propidium Monoazide Viability PCR

Contact Info

Product

Resources

About